Sarepta Therapeutics has provided additional safety data on its gene therapy Elevidys as a Duchenne muscular dystrophy ...

Keros Therapeutics (KROS)’ treatment of Duchenne muscular dystrophy was granted FDA orphan designation, according to a post to the agency’s site.

Managing osteoporosis and bone health in Duchenne muscular dystrophy occurs in a high-risk environment for fractures due to disease-related loss of muscle and movement, adverse effects of ...

Dyne Therapeutics Inc. (NASDAQ: DYN) is one of the best small cap stocks with biggest upside potential. On August 4, Dyne ...

Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), is pleased to announce the expansion of its leadership team with the ...

Ryuji Morizane, MD, PhD, of the Department of Medicine at Massachusetts General Hospital, is the senior/corresponding author ...

Delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), showed high dystrophin expression and a favorable safety profile in young patients. Delandistrogene moxeparvovec ...

Teen whose story touched Post readers gets up-close look at planes and hangars, joining his friends for ‘special’ visit he ...

Charlie has Duchenne muscular dystrophy, a degenerative genetic disease that, until recently, has guaranteed death by early adulthood from cardiac or respiratory failure.

Dr. Jerry Mendell, who co-invented the gene therapy, said "treating boys with Duchenne muscular dystrophy after seeing their natural history and decline over and over and over for the past 50 ...

Global Duchenne Muscular Dystrophy Drugs Market Report 2023: Sector is Expected to Reach $4 Billion by 2028 at a CAGR of 11.88% - ResearchAndMarkets.com May 18, 2023 07:21 AM Eastern Daylight Time ...

After decades of research, gene therapy has been approved for Duchenne Muscular Dystrophy, a degenerative muscle disease diagnosed each year in about 1 in 3,500 newborns, almost all boys.